Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More good news, but that ****ing CE has got to go already.
Just grabbed another 150,000 shares. $ILUS strong!
This is a great CEO!!! (CYBL could learn a thing or 2 from this guy about dealing with the OTCM).
No, but there may be a thesaurus award!
I know there was no meeting on the 26th, but did anyone attend or did any information come out of the luncheon? $ILUS
Happy New Year!!!!!!
Happy New Year to all !!!! $CYBL 2024! Let's hope the CE goes bye-bye in early 2024.
Maybe it's wishful thinking or premature annunciation.
Third Quarter 2023 Financial and Operating Highlights:
Net revenue of $5.8 million increased 175% year over year;
Sales volume increased by 326% year over year and 27% sequentially quarter over quarter to 298 vehicles;
Average selling price (“ASP”) increased 15.7% year over year to approximately $19,200; and
Adjusted EBITDA for the quarter is a loss of $12.1 million compared to a loss of $12.0 million for Q3 2022.
Peter Z. Wang, Chief Executive Officer explained, “Our sales momentum in the third quarter continued to ramp up as distribution expanded from the second quarter of 2023. Consequentially, we have sold 298 vehicles in Q3 2023 compared to 235 vehicles in Q2 2023 and 70 in Q3 2022. More importantly, to date the demand for some of our newly launched vehicle models in Europe such as the LS260® has outpaced our estimates. We have also experienced positive sales momentum for our iChassis, having sold 103 units in Q3, though these 103 units are not inclusive of the number of vehicles sold because iChassis is not considered a complete vehicle. We continue to build our sales momentum in 2023 from quarter to quarter to improve the effectiveness of our sales process, including having streamlined our North American sales team structure during Q3 2023.
Cenntro Electric Group Announces Third Quarter 2023 Unaudited Financial Results
Yep, per norm.
Must have corrected, I'm seeing .0359. $ILUS
Looking forward to that, and to what the dividend announcement will be re: QIND/ILUS tomorrow.
Agreed. And at the very least, we'll get some new eyes on $ILUS which is a good thing.
It really is incredibly frustrating. :( $CYBL
Finished +25% today. Something going on? $SSET
And... the CE is still there. :( Yet, I remain optimistic about CYBL overall.
I watched it yesterday and I'm not seeing it listed anymore either. Looks like he took it down??
Larger investors, hedge funds, brokerages, etc. avoid the OTC Pink. Moving to the OTCQB will put new eyes on ILUS.
When that CE comes off, this is going to recover quickly. Just tried to add a bunch, but TD Ameritrade wasn't having it. $CYBL
My brain hurts, so I don't want to speculate. Any reason for the 30% slide? $CYBL
That is good news! $SSET
Good news. I'll take it when I can get it. LOL
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
4:05 pm ET January 4, 2023 (Globe Newswire) Print
GlobeNewswireJanuary 04, 2023
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors.
"We are thrilled to have Jill join the Oncternal board of directors. Jill's accomplishments building a multi-billion dollar oncology business in the U.S. are a great fit for supporting Oncternal's transition into a late-stage oncology company," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO. "As we embark into our first global Phase 3 registrational study Zilo-301, we will greatly benefit from her guidance to help us build a compelling patient-centric value proposition for Zilovertamab."
Ms. DeSimone was most recently President of U.S. Oncology at Merck & Co., Inc., where she built the company's oncology division, growing it to over a $9 billion business in just eight years. She led three key product launches and more than 45 indication launches, including Keytruda(R). Prior to joining Merck, she served as senior vice president of Global Women's Health at Teva Pharmaceutical Industries Ltd from 2012 to 2014. Prior to her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including senior vice president of U.S. Oncology & Commercial from 2010 to 2012 and senior vice president of U.S. Virology/HIV from 2006 to 2010. Ms. DeSimone currently serves as a member of the board of directors of Praxis Precision Medicines, Inc. and Affini-T Therapeutics Inc. She also serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that delivers non-medical aid for individuals undergoing cancer treatment. Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania.
"I am honored to join the board at Oncternal, as it continues to advance its first-in-class late-stage oncology pipeline," said Ms. DeSimone. "I believe Zilovertamab and ROR1 can play a key role in addressing significant unmet needs in hematological malignancies and solid tumors, and I look forward to working with the board at Oncternal to continue to bring important therapeutic innovations to patients."
I agree $AAPT will see its time, but IMO that CE needs to go bye-bye first.
I think some may be tired of the long silent period and are selling for EOY tax loss.
Fingers crossed that AAPT is the winning word!! I am at work right now, but when I play Scrabble tonight, I will definitely take a screen cap if the ad comes up again.
I was playing Scrabble online last night and also saw ads for AAPT. I was surprised but pleased! :D
Outstanding news! Of course, given the current market as a whole, who knows how PPS will play out today. But sooner or later $ILUS will be in the $$$ range where it should be, and we all know it.
This does NOT represent dilution. They are issuing "b shares" which, in the future, can be converted to common shares. This is not a bad thing.
Karen's letter to shareholders: $PUGE
Totally true. RSI on the 20-day is 33! $AAPT
Nice! $NAKD
Happy Thanksgiving $ILUS Family!!! Can't wait to see our new cars and boats in the coming year.
The official quarterly report is out on OTC Markets. $CYBL Q3
$NAKD on fire premarket.